Compare PYXS & MGYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PYXS | MGYR |
|---|---|---|
| Founded | 2018 | 1922 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.3M | 123.2M |
| IPO Year | 2021 | 2021 |
| Metric | PYXS | MGYR |
|---|---|---|
| Price | $1.73 | $22.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $8.22 | N/A |
| AVG Volume (30 Days) | ★ 797.9K | 6.8K |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 2.19% |
| EPS Growth | 3.03 | ★ 26.83 |
| EPS | N/A | ★ 1.47 |
| Revenue | ★ $13,858,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14,188.99 | N/A |
| P/E Ratio | ★ N/A | $14.86 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.03 | $16.03 |
| 52 Week High | $5.55 | $23.99 |
| Indicator | PYXS | MGYR |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 62.38 |
| Support Level | $1.59 | $16.88 |
| Resistance Level | $1.84 | N/A |
| Average True Range (ATR) | 0.14 | 0.80 |
| MACD | 0.03 | 0.15 |
| Stochastic Oscillator | 45.74 | 53.77 |
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Magyar Bancorp Inc is an independent, community financial services provider offering traditional banking services to individual, business, and government customers. The Company attracts retail deposits through its main office in New Brunswick, New Jersey, and branch offices in Middlesex and Somerset Counties, and invests those funds mainly in commercial and residential real estate loans, commercial business loans, SBA loans, home equity loans and lines of credit, construction and land loans, and investment securities. Revenues are derived mainly from interest on loans and securities and from fees and service charges, with lending relationships focused on small to mid-sized businesses and individual consumers in central and northern New Jersey.